Literature DB >> 2565690

Progression to AIDS in patients with lymphadenopathy or AIDS-related complex: reappraisal of risk and predictive factors.

H W Murray1, J H Godbold, K B Jurica, R B Roberts.   

Abstract

PURPOSE: In 1985, we reported that acquired immunodeficiency syndrome (AIDS) developed in 14 of 81 (17%) men with generalized lymphadenopathy followed prospectively for an average of 13 months. The presence of oral thrush or constitutional symptoms, or both, or severely impaired T4+ cell responses to specific antigen (interferon-gamma production) accurately identified patients at immediate risk for AIDS. The purpose of the current report is to describe the progress of these 81 patients during the three and a half years since enrollment and to include new data on initial serum levels of beta 2 microglobulin and human immunodeficiency virus (HIV) p24 antigen. PATIENTS AND METHODS: The mean age of the 81 patients was 35.4 years; 79 were homosexuals and two were drug abusers. Immunologic testing was performed once at the time of enrollment in all patients. Seventy-seven of the 81 patients were seropositive for HIV antibody. Frozen samples of serum, also obtained at initial study, were assayed in 1988 for beta 2 microglobulin and HIV p24 antigen. The clinical status of patients was determined six, 14, and 36 months after enrollment was closed (June 1984) by either interview and examination or telephone contact with private physicians.
RESULTS: After three and a half years of follow-up, 42 patients have developed AIDS, including (1) 77% who had had thrush or symptoms, or both, (2) 80% to 88% of those who originally demonstrated marked immunologic abnormalities (skin test anergy, less than 200 T4+ cells/mm3, T4/T8 cell ratio of less than 0.5, severely impaired interferon-gamma production [less than 25 U/mL], or elevated serum beta 2 microglobulin level [greater than 3.0 mg/L], and (3) 95% of patients with HIV p24 antigenemia. However, AIDS also developed in 51% of patients who had had more apparently benign initial manifestations (lymphadenopathy alone, herpes zoster), in 41% to 54% despite normal initial results for either T4+ cell number, interferon-gamma secretion, beta 2 microglobulin, or skin testing, and in 44% of those whose sera did not contain HIV antigen.
CONCLUSION: These updated results demonstrate the remarkably poor prognosis of patients with generalized lymphadenopathy or AIDS-related complex irrespective of initial clinical, immunologic, and serologic findings, and suggest that essentially all such persons may be candidates for antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2565690     DOI: 10.1016/0002-9343(89)90380-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

Review 1.  Infection and infectious diseases.

Authors:  P D Welsby
Journal:  Postgrad Med J       Date:  1990-10       Impact factor: 2.401

Review 2.  Antiretroviral therapy for human immunodeficiency virus infection in 1997.

Authors:  D A Katzenstein
Journal:  West J Med       Date:  1997-05

3.  Clinical utility of an enhanced human immunodeficiency virus type 1 p24 antigen capture assay.

Authors:  M B Vasudevachari; N P Salzman; D R Woll; C Mast; K W Uffelman; G Toedter; D Hoefheinz; J A Metcalf; H C Lane
Journal:  J Clin Immunol       Date:  1993-05       Impact factor: 8.317

4.  Prospective study of antigenemia, plasma viremia and lymphocytic viremia in HIV-infected hemophiliacs.

Authors:  S Melón Garcia; M de Oña Navarro; C Rodriguez Pinto; M Fernández Urgellés; A Martinez Gutierrez; P de la Iglesia; F J Mendez García
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

5.  Transplantation in HIV+ patients.

Authors:  A G Tzakis; M H Cooper; J S Dummer; M Ragni; J W Ward; T E Starzl
Journal:  Transplantation       Date:  1990-02       Impact factor: 4.939

6.  Low-dose zidovudine in combination with either acyclovir or lymphoblastoid interferon-alpha in asymptomatic HIV-infected patients: a pilot study.

Authors:  R Weber; A Bonetti; J Jost; M W Vogt; B Spacey; W Siegenthaler; R Lüthy
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

7.  Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons.

Authors:  M D Stein; J Piette; V Mor; T J Wachtel; J Fleishman; K H Mayer; C C Carpenter
Journal:  J Gen Intern Med       Date:  1991 Jan-Feb       Impact factor: 5.128

8.  Previously Unidentified Single Nucleotide Polymorphisms in HIV/AIDS Cases Associate with Clinical Parameters and Disease Progression.

Authors:  Vladimir V Anokhin; Liliia B Bakhteeva; Gulshat R Khasanova; Svetlana F Khaiboullina; Ekaterina V Martynova; Richard L Tillett; Karen A Schlauch; Vincent C Lombardi; Albert A Rizvanov
Journal:  Biomed Res Int       Date:  2016-12-05       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.